LPCN lipocine.com Net earnings per share for the last 12 months

Public company logo of Lipocine Inc. (LPCN)

The current level of rolling earnings per share demonstrates yield dynamics where the -1.36 indicator determines the metric's magnitude. This volatility is linked to the development of oral hormone delivery systems that replace injections and increase license values. The high authority of Lipocine Inc. (LPCN) among endocrinologists is clinically proven, yet its financial strength is based on patent payments from partners.

LPCN (Lipocine Corporation) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/15/2026

Analytical breakdowns and data insights for company Lipocine Corporation (LPCN)

- stock price and consensus target price:
Stock Price Lipocine Corporation|LPCN - Average Forecast Price
- market capitalization data:
Market Valuation Lipocine Inc.|LPCN - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Lipocine|LPCN - Book Capitalization|Market Capitalization to Book Value Ratio lipocine.com|LPCN - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Lipocine Inc.|LPCN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Lipocine Inc.|LPCN - Company Debts|Debts to Book Capitalization Lipocine|LPCN - Long-Term Debt Volume|Company Short-Term Debt Lipocine|Quick Liquidity lipocine.com
- net income and valuation multiples indicators:
LPCN - Net Income|Expected Profit Lipocine Inc.|LPCN - Price to Earnings Ratio|Forward P/E Multiple Lipocine Corporation|LPCN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lipocine Inc|LPCN - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Lipocine|LPCN - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth lipocine.com|LPCN - Net earnings per share growth this year|Earnings growth forecast for next year Lipocine Inc.
- sales and revenue data:
LPCN - Company Gross Revenue|Company Projected Revenue Lipocine Corp|LPCN - Market Cap to Revenue Ratio|Forward P/S Multiple Lipocine Inc.|LPCN - Trailing Twelve Months Revenue Growth
Fundamental company valuation:Lipocine Inc (LPCN)
Mass-produced product of Lipocine Corp

Investors require an objective tool to measure the operational efficiency of Lipocine Inc. (LPCN). This rolling per-share profit metric is calculated as the ratio of annual net income to the total number of shares. The upward trend of the curve confirms the fundamental stability of the business. For this leader in oral endocrinology, the metric reflects the monetization of the transition from injections to tablets. The positive momentum of the indicator signals the market success of innovative hormone delivery forms.

Competitors of Lipocine Inc.

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS